MarketPulse

immunosequencing

3 articles
The Motley FoolThe Motley Fool··Robert Izquierdo

Adaptive Biotech COO Sells $271K in Stock, But Company's Growth Story Remains Intact

Adaptive Biotechnologies COO Julie Rubinstein sold 19,037 shares worth $271,000 under a pre-planned trading arrangement, retaining substantial equity as the biotech firm posts strong 55% revenue growth.
ADPToperating lossesrevenue growth
The Motley FoolThe Motley Fool··Cory Renauer

ADPT Executive's $826K Share Sale Signals Liquidity Play, Not Loss of Confidence

$ADPT's President/COO sold $826K in shares via option exercise while retaining 408K shares. MRD revenue grew 46%; Medicare coverage expansion supports growth outlook.
ADPTexecutive compensationbiotechnology
The Motley FoolThe Motley Fool··Jonathan Ponciano

Adaptive Biotech COO Sells $2.4M in Stock as Revenue Surges 55% YoY

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.
ADPTrevenue growthEBITDA